Selinexor Plus Ruxolitinib in JAK Inhibitor-Naïve Patients: Updated Results From XPORT-MF-034


Andrew Kuykendall, MD, highlights the potential of selinexor plus ruxolitinib in JAK inhibitor-naïve patients with MF based on promising response rates in XPORT-MF-034 updated results, with plans for a phase 3 study. He also noted the need to manage nausea as a adverse effect.

Related Videos
Akriti Jain, MD
Mikkael A. Sekeres, MD, MS
Alessandra Ferrajoli, MD
Somedeb Ball, MBBS, assistant professor, medicine, Division of Hematology Oncology, Department of Medicine, Vanderbilt University Medical Center
Mikkael A. Sekeres, MD, MS
Naseema Gangat, MBBS
Dipti Patel-Donnelly, MD, Johns Hopkins
Jasmin M. Zain, MD